Home > Dermatology > EADV 2019 > Late-Breaking News > JAK inhibition plus TCS lead to high clearance rates in AD

JAK inhibition plus TCS lead to high clearance rates in AD

Presented By
Prof. Kristian Reich, Georg-August-University Göttingen, Germany
Trial
Phase 3, BREEZE-AD7
In addition to skin clearance, baricitinib in combination with topical corticosteroid (TCS) showed to be particularly effective in pruritus reduction and improvement of sleep in adult patients with moderate-to-severe atopic dermatitis (AD) [1]. Baricitinib is a selective Janus kinase (JAK) 1 and 2 inhibitor that has previously shown to be effective in moderate-to-severe AD when given as monotherapy. The BREEZE-AD7 study is the first phase 3 study testing the efficacy of a JAK inhibitor in combination with low- and moderate-potency TCS therapy. “I think the BREEZE-AD7 study is important because it allows to look more into the real world where we use a systemic drug together with TCS,” said Prof. Kristian Reich (University Medical Center Hamburg-Eppendorf, Germany). The study included 329 adult patients with moderate-to-severe AD for ≥ 1 year. Participants were treated in 3 arms: either placebo and TCS, or baricitinib in a dose of 2 or 4 mg and TCS. P...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on